Dr. Reddy’s Laboratories introduces FDA-approved Nerivio for migraine management in India


Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, has announced the rollout of Nerivio in India. This state-of-the-art, United States Food and Drug Administration (USFDA) approved wearable therapy device offers a drug-free option for managing migraines. Migraine is a prevalent global health challenge, significantly impacting women, who make up about 60% of the 213 million migraine sufferers in India.

Nerivio: A Breakthrough in Migraine Management

Nerivio is a prescription-based, non-invasive device intended for acute and prophylactic treatment of migraines in adults and adolescents aged 12 years and above. The device, worn on the upper arm, uses Remote Electrical Neuromodulation (REN) to activate a natural pain-relieving process in the brainstem.

Dr. Reddy’s Laboratories launches FDA-approved migraine device, Nerivio, in India

Dr. Reddy’s Laboratories launches FDA-approved migraine device, Nerivio, in India

Dr. Reddy’s Entry into Digital Therapeutics

M.V. Ramana, CEO of Branded Markets (India and Emerging Markets) at Dr. Reddy’s, emphasized the significance of this launch: “The rollout of Nerivio marks our entry into digital therapeutics. It is an area seeing increasing adoption due to its potential to reduce pill burden and decrease dependency on non-specific medication. Nerivio is a USFDA-approved, drug-free, non-invasive, first-of-its-kind product for migraine in India and offers a favorable safety profile. We believe this product meets a genuine unmet clinical need among migraine patients.”

See also  ABVP calls for statewide school strike in Telangana, demands for improved infrastructure

Global Reach and User-Friendly Application

Nerivio’s unique app, available on Google Play Store and Apple app store, allows users to control the device’s intensity levels and log symptoms. Dr. Reddy’s has also signed exclusive agreements for the marketing and distribution of Nerivio in several European countries, expanding its global reach.

See also  Carlyle Group takes stake in SBI Life Insurance

Dr. Reddy’s Laboratories’ launch of Nerivio in India represents a major step in addressing the migraine disease burden. The introduction of this innovative, non-invasive therapy device is poised to significantly improve the well-being, quality of life, and productivity of migraine sufferers.

Share This